Community health center leaders have created a new membership organization—Advocates for Community Health (ACH)—to influence federal health care policy and “drive a new vision for the role health centers can and should play in an evolving 21st century health care
…
Lynn Barr, the founder and executive chair of a company that helps health systems implement value-based payment models and maximize 340B savings, has been appointed to the Medicaid Payment Advisory Commission (MedPAC).
U.S. Comptroller General Gene Dodaro announced Barr’s appointment
…
A federal district judge in Trenton, N.J., this week denied drug makers’ Novo Nordisk and Sanofi’s motions to temporarily stop federal health officials from forcing the companies to immediately resume offering 340B pricing when covered entities use contract pharmacies. If
…
340B disproportionate share (DSH) hospital outpatient departments are more likely than other hospital outpatient departments and independent physician offices to treat Medicare beneficiaries with chronic conditions who are Black, disabled, or who have low incomes, a new 340B hospital-funded study
…
The U.S. Centers for Medicare & Medicaid Services (CMS) has proposed to delay implementing a portion of a regulation encouraging value-based purchasing for drugs in the Medicaid program that may lead to drugs having multiple best prices.
Finalized during the
…
Drug manufacturer Sanofi yesterday sent the U.S. Health Resources and Services Administration (HRSA) a 30-page defense of its requirement that 340B covered entities must submit their contract pharmacy claims data to a vendor to continue to be able to access
…
National hospital groups urged the U.S. Supreme Court last Friday to review and reverse a federal appellate decision upholding a steep cut in hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.
The American Hospital Association (AHA), the Association of American
…
Drug manufacturers Xellia Pharmaceuticals and Chartwell Rx have notified 340B covered entities about possible refunds for overcharges.
Xellia Pharmaceuticals
Xellia notified 340B covered entities about refunds for overcharges on 16 NDCs for its antibiotics vancomycin, daptomycin, and colistimethate.
Xellia posted
…
Chiquita Brooks-LaSure last Thursday was formally sworn in as Administrator of the Centers for Medicare and Medicaid Services (CMS), setting in place another key Biden administration official with influence on the 340B program.
Although CMS does not control federal 340B
…
Community Voices for 340B (CV340B), the first non-profit grassroots organization focused on promoting the importance of the 340B program, kicked off the first of series of regional educational webinars scheduled last week. The event, which was focused on the Northeast
…*Sign up for news summaries and alerts from 340B Report